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EBV-ASSOCIATED LEIOMYOMAS FOLLOWING HAPLOIDENTICAL
TRANSPLANTATION FOR X-LINKED SEVERE COMBINED IMMUNODEFI-
CIENCY DISEASE
Robertson, K.A.1, Alturi, S.1, Neville, K.1, Davis, M.1,
Marshalleck, F.E.1, Buckley, R.H.2, Nelson, R.P.1 1Indiana University
School of Medicine, Indianapolis, IN; 2Duke University Medical Center,
Durham, NC.
In the setting of transplantation, Epstein-Barr virus (EBV) is
most commmonly associated with posttransplantation lymphopro-
liferative disease; however, there are reports of EBV associated
leiomyomas for which the virus has some tropism. We wish to
report the ﬁrst case of EBV-associated leimyomas following hap-
loidentical BMT for X-linked severe combined immune deﬁciency
(SCID). Twin A is an 8-year-old boy who along with his syngeneic
twin (B) received a paternal T-cell–depleted haploidentical BMT
for X-linked SCID at 10 days of life. Twin B experienced rapid
donor T-cell engraftment with restored cellular function. Twin A’s
course was complicated by incomplete donor T-cell engraftment,
multiple infections, and GVHD. Twin A received a booster twin-
to-twin infusion of unfractionated marrow, resulting in an im-
proved lymphocyte counts, mitogen stimulation response, and
clinical improvement without worsening of GVHD. The patient
(twin A) did well over the next 6 years until he developed fatigue,
weight loss, and exercise-induced shortness of breath. CT scans
revealed bilateral renal masses (4 on the right and 2 on the left)
with a left pleural-based lung mass. Percutaneous renal biopsy
demonstrated leiomyoma with a spindle cell histology. The tumor
cells were positive for Ki-67 and actin, but negative for S-100
protein and HMB45. EBV PCR on parafﬁn-embedded tissue was
positive. EBV serologies were unhelpful on both twins as they
remain on intravenous immunoglobulin supplementation, but
EBV PCR was negative from the peripheral blood of twin B and
positive for twin A at 2400 copies per mL. T-cell chimerism studies
showed a decrease in donor T-cell engraftment in twin A. Twin A
continued to show weight loss with persistant symptoms and was
subsequently given an infusion of 106 peripheral blood lympho-
cytes per kg body weight from twin B to supplement his graft. Over
the next 4 months, the patient (twin A) has shown an increase in
T-cell numbers, improvement in clinical symptoms, weight gain,
and stabilization of his leiomyomas.
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RESULTS OF THE CORD BLOOD TRANSPLANTATION STUDY (COBLT):
CLINICAL OUTCOMES OF UNRELATED DONOR UMBILICAL CORD
BLOOD TRANSPLANTATION IN PEDIATRIC PATIENTS WITH INBORN
ERRORS OF METABOLISM
Kurtzberg, J.1, Carter, S.L.2, Sahdev, I.3, Wall, D.4, Pietryga, D.5,
Wagner, J.E.6, Kernan, N.A.7 1Duke University Medical Center,
Durham, NC; 2/ The EMMES Corporation, Rockville, MD; 3Schneider
Children’s Hospital, New Hyde Park, NY; 4Texas Transplantation
Institute, San Antonio, TX; 5DeVos Children’s Hospital, Grand Rapids,
MI; 6University of Minnesota, Minneapolis, MN; 7Memorial Sloan-
Kettering Cancer Center, New York, NY.
The Cord Blood Transplantation Study (COBLT), sponsored by
the National Heart, Lung, and Blood Institute, evaluated the
outcomes of unrelated donor umbilical cord blood transplantation
(UCBT) in 32 patients (56% males; 75% Caucasian) with inborn
errors of metabolism. A common protocol was used for the pre-
parative regimen (busulfan, cyclophosphamide, ATG) and GvHD
prophylaxis (cyclosporine and steroids). Patients with MPS I Hurl-
er’s syndrome (n  13; 12 reported NEJM 2004:350:1960–9),
Hurler-Sheie syndrome (n  2), Sanﬁlippo’s syndrome (n  2),
I-cell disease (n  1), Krabbe’s disease (n  7), Tay-Sachs disease
(n 2), and adrenoleukodystrophy (n 5) with a mean age of 1.83
years were transplanted with an HLA 6/6 (n 3), 5/6 (n 14), 4/6
(n  14), or 3/6 (n  1) matched unit with a median of 8/6  107
nucleated cells/kg selected from COBLT banks (80%) or other
banks (20%). CBUs were screened for enzyme activity to prevent
use of a carrier donor. The cumulative incidence of neutrophil
engraftment and grade III/IV acute GvHD were 84% in a median
of 26 days and 19%, respectively. The probability of survival at 180
days and 2 years was 84%. Seven patients died, 1 before and 6 after
transplantation (1 of GvHD with infection, 3 of graft failure, 2 of
organ failure, and 1 of hemolytic anemia). The surviving patients
with MPS syndromes, Tay-Sachs disease, and Krabbe’s disease all
stabilized and/or gained skills posttransplantation. One of 5 pa-
tients with ALD experienced disease progression, whereas all oth-
ers stabilized and continue to gain developmental skills. Levels of
HLA disparity between recipient and donor determined by retro-
spective high-resolution DNA typing did not inﬂuence engraft-
ment, GvHD, or overall survival. The COBLT study represents
the ﬁrst prospective multicenter trial in children with inborn errors
of metabolism undergoing UCBT. UCBT provides rapid access to
donors and favorably alters the natural history of the disease and
should be considered for patients with metabolic diseases who are
eligible for transplantation therapy.
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BUSULFAN DOSE ESCALATION TO INCREASE GENE MARKING OF HE-
MATOPOIETIC STEM CELLS BY LENTIVIRAL VECTORS IN INFANT RHE-
SUS MONKEYS
Kohn, D.B.1, Kahl, C.A.1, Lee, C.I.2, Jiminez, D.F.2, Choi, C.1,
Pepper, K.A.1, Petersen, D.1, Fletcher, M.D.2, Leapley, A.C.2,
Burns, T.S.2, Ultsch, M.-N.2, Tarantal, A.F.2 1Childrens Hospital Los
Angeles, Los Angeles, CA; 2California National Primate Research Cen-
ter, Davis, CA.
Gene transfer to hematopoietic stem cells (HSCs) using lentiviral
vectors may be an attractive approach to treat a variety of diseases.
This can be accomplished in the context of an autologous bone
marrow transplantation (BMT), where HSC are transduced ex
vivo. The myeloablative drug busulfan can then be used to “make
space” in the bone marrow compartment, to allow efﬁcient reen-
graftment of the transduced cells. It is important to identify an
optimal busulfan dose that will result in efﬁcient long-term gene
marking and have the least toxicity. We performed a lentiviral
gene-marking study in infant rhesus macaques using escalating
doses of busulfan. Bone marrow (10–15 mL/kg) was harvested
from each monkey, followed by a single IV infusion of busulfan
over 2 hours in groups of 2–3 using busulfan at 0, 40, 80, 120, and
160 mg/m2 with dilantin seizure prophylaxis. Peripheral blood
busulfan levels were then followed over a period of 4 hours, and the
AUC was determined. CD34 cells were isolated from the har-
vested bone marrow, cultured for 24 hours in serum-free medium
with recombinant cytokines and transduced overnight with an
SIV-derived lentiviral vector pseudotyped with the VSV-G glyco-
protein. The vector contains a neomycin gene with a mutation in
the start codon that abolishes its expression and thus can serve as a
nonexpressed marker gene. The next morning, transduced cells
were washed and reinfused IV, approximately 48 hours after ad-
ministration of busulfan. Increasing dosages of busulfan resulted in
an increased AUC. However, variability in AUC at each dose level
( 1.5) was observed, suggesting relatively large interindividual
variations in busulfan clearance. At doses of 120 and 160 mg/m2
busulfan, neutrophil counts transiently dropped under 1000 cells/
L, and platelet counts dropped under 105/L, indicating dose-
related neutropenia and thrombocytopenia. Blood chemistries and
behavior appeared normal in all animals, and no seizures were
observed. Gene marking in mononuclear cells and granulocytes
will be measured at monthly intervals by determining the number
of integrated proviruses per cell with quantitative PCR. Together,
our results suggest that busulfan is safe and has no detectable
toxicity at these submyeloablative dosages in infant rhesus mon-
keys, except for the expected myelosuppressive effects.
We thank ESP Pharma for providing Busulfex for these studies.
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ENGRAFTMENT FOLLOWING REDUCED INTENSITY CONDITIONING
(RIC) WITH FLU-BU-ATG AND ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION (HSCT)—PEDIATRIC EXPERIENCE AT CHIL-
DREN’S MEMORIAL HOSPITAL
Duerst, R.E., Jacobsohn, D.A., Tse, W., Kletzel, M. Children’s Memo-
rial Hospital and Feinberg School of Medicine, Northwestern University,
Chicago, IL.
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We report the experience of 41 patients (21 males, 20 females;
mean age, 8.1 years; range, 0.2–22.6 years) treated with RIC and
allogeneic HSCT. Diagnoses consisted of malignancies in 24 (20
hematologic and 4 refractory neuroblastoma) and nonmalignant
disorders in 17: immunodeﬁciencies in 6, metabolic disorders in 5,
hemoglobinopathies in 4, and aplastic anemia in 2. Twelve patients
had prior HSCT (7 autologous and 5 allogeneic). Recipient’s racial
origins included 22 Caucasian, 10 Hispanic, 7 African American,
and 2 Asian. A standardized RIC regimen comprised of ﬂudara-
bine, 30 mg/m2 for 6 days (days 10 to 5), followed by intrave-
nous busulfan, 0.8–1 mg/kg for 8 doses or targeted busulfan at
AUC 4000 mmol/min for 2 doses (days 5 and 4) and equine
ATG, 40 mg/kg or rabbit ATG, 2 mg/kg for 4 days (days 4
through1) was administered. Graft-versus-host disease (GVHD)
prophylaxis was cyclosporin A (CsA) alone in 19 patients and CsA
and mycophenolate mofetil in 22 patients. Growth factor support
was not used. Stem cell sources included 27 unrelated donors and
14 related donors; 34 of 41 sources were peripheral blood stem
cells. We also assessed engraftment by determining the number of
days required to achieve  50% and  95% donor chimerism
(Do-chim) by VNTR in total leukocyte and T-lymphocyte (CD3)
populations.
The median cell doses infused were 5.8  108 MNC/kg and 2 
106 CD34 cells/kg. Seven of 41 patients failed to engraft, and 3
patients were not evaluable due to early deaths from toxicity (in 2)
or relapse (in 1). Four of 16 evaluable patients with nonmalignant
disorders failed to engraft versus 3 of 22 with malignancies. Pa-
tients failing to engraft were younger (median age, 6.3 vs 8.8 years)
and weighed less (median weight, 18 vs 27 kg), but received lower
cell infusion doses (3.9 vs 5.9  108 MNC/kg; P  .05). The
median time to a postnadir ANC of 500/L was 16.5 days, and
unsupported platelet count  20,000/L was 19 days. Data shown
in the table indicate trends for more rapid achievement of Do-chim
in patients treated for malignancy. Also, within the 14 malignancy
patients, those with clinically signiﬁcant acute (II-IV) and/or ex-
tensive chronic GVHD demonstrated faster Do-chim.
These measures of engraftment may provide a reproducible com-
parison of engraftment in the setting of RIC and resulting mixed
chimeric states. These parameters may provide insight to promote
engraftment or to balance a desired graft-versus-tumor effect in
patients with malignancies versus limitation of GVHD for patients
with no beneﬁt from an excessive alloimmune response.
Table 1. Median Number of Days to Achieve Donor-Chimerism
Leukocyte
Do-chim
50
Leukocyte
Do-chim
95
Lymphocyte
Do-chim
50
Lymphocyte
Do-chim
95
Evaluable Pts
(n  26) 18 26 25 33
Non-malignant
Disorders
(n  11) 19 53 26 82.5
Malignancy Pts
(n  15) 13 25 21 27
Malignancy &
GVHD
(n  7) 13 17 20 19
Malignancy
without
GVHD
(n  8) 16 32.5 26.5 39
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CHANGE OF RISK FACTORS FOR TREATMENT-RELATED MORTALITY IN
CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION FOR MALIGNANT AND NONMALIGNANT DISEASES
Peters, C.1, Lawitschka, A.1, Atarbaschi, A.1, Lion, T.2, Poetschger, U.2,
Fritsch, G.2, Fischer, G.3, Rosenmayr, A.3, Gadner, H.1,
Matthes-Martin, S.1 1St. Anna Children’s Hospital; 2Children Cancer
Research Institute; 3University Clinic for Blood Group Serology and
Transfusion Medicine; 4Austrian Stem Cell Registry, Vienna, Austria.
Allogeneic hematopoietic stem cell transplantation (HSCT) of-
fers a high chance for cure in patients with nonmalignant disorders.
However, acute and late complications as consequence of the
conditioning regimen and severe immunosuppression are still a
matter of concern. Only few studies speciﬁcally focused on the risk
for treatment-related mortality (TRM) in children. To evaluate
factors inﬂuencing the outcome after HSCT we retrospectively
analyzed 342 children given allogeneic SCT. The median age was
8.7 years; 230 patients suffered from hematologic malignancies,
112 from nonmalignant disorders (SAA, immunodeﬁciency syn-
dromes, metabolic disorders, thalassemia, sickle cell disease, he-
mophagocytic syndromes). The 360-day TRM (in nonmalignant
diseases, 0.17) was inﬂuenced by donor type (HLA-identical sibling
donors vs phenotypically matched family or unrelated donors vs
mismatched donors), time of SCT (before and after 1997), stage of
disease (early vs advanced), conditioning regimen (myeloablative vs
reduced), graft manipulation (T-cell depletion vs no TCD) and
history of severe organ dysfunction and/or infections. Most fre-
quent causes of death were organ toxicity, acute GvHD, and
infections. The following factors were independent risk factors for
TRM: graft failure, resistant disease, CMV IgG-negative donors
for CMV IgG-positive patients, HLA mismatch  2 alleles, TCD
graft, and history of severe toxicity and/or infection. The pattern of
severe adverse events changed over time. In the ﬁrst years, GvHD
was the most frequent life-threatening complication, followed by
toxicity and infections. More recently, viral infections are the
major reason for TRM, particularly in patients transplanted from
HLA-mismatched donors given T-cell–depleted grafts. The cu-
mulative incidence of TRM in patients transplanted after 1997 was
0.06 from matched sibling donors, 0.14 from unrelated donors, and
0.27 and from HLA-mismatched donors. Factors associated with
improved survival incuded the quality of HLA typing (high-reso-
lution techniques in HLA class I and II), reduced intensity condi-
tioning, monitoring and preemptive treatment (pharmacologic and
virus-speciﬁc cell support) of viral infections, and experience (cen-
ter size  10 allogeneic SCTs vs  10 per year). We conclude that
today, the risk for TRM especially in children with nonmalignant
diseases undergoing HSCT could be reduced by multidisciplinary
approaches focusing the enhancement of immunologic reconstitution.
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TREATMENT OF PEDIATRIC PATIENTS WITH SANFILIPPO SYNDROME
(MPS IIIA AND IIIB) WITH UNRELATED UMBILICAL CORD BLOOD
TRANSPLANTATION
Kurtzberg, J.1, Szabolcs, P.1, Wood, S.1, Ciocci, G.1, Driscoll, T.1,
Prasad, V.1, Parikh, S.1, Martin, P.L.1, Allison, J.1, Escolar, M.L.2
1Duke University Medical Center, Durham, NC; 2University of North
Carolina at Chapel Hill, Chapel Hill, NC.
Umbilical cord blood transplantation (UCBT) favorably alters
the natural history of young pediatric patients with Hurler syn-
drome (MPS I). We asked whether it would also be effective for
patients with Sanﬁlippo syndrome (MPS III). Patients with San-
ﬁlippo syndrome have less somatic and more CNS disease than
patients with other MPS syndromes. They are typically diagnosed
between 3 and 5 years of age. Without treatment, they develop
severe neurologic dysfunction, deafness, inability to speak or am-
bulate, and severely autistic behaviors. Death occurs between 10
and 13 years of age. Currently, allogeneic stem cell transplantation
(SCT) is the only way to deliver healthy enzyme to the brain. We
hypothesized that children with Sanﬁlippo syndrome would beneﬁt
from UCBT, particularly if it was performed early in the course of
the disease. Between February 2001 and April 2004, 12 children
(age 10–59 months, 75% male, 100% Caucasian) underwent
UCBT. All were prepared for transplantation with myeloablative
chemotherapy (busulfan/cyclophosphamide/ATG), and all re-
ceived prophylaxis against GvHD with cyclosporine and steroids.
They were transplanted with unrelated donor UCB grafts match-
ing at 6/6 (n  1), 5/6 (n  7), and 4/6 (n  4) HLA loci,
containing a median of 6.5 107 nucleated cells/kg and 1.42 105
CD34 cells/kg. Donor cell engraftment (ANC 500/L) occurred
in 9 of 12 children in a median of 24 days. Platelet engraftment
(platelet count 50K/L untransfused) occurred in 7 of 12 children
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